hi everyone,
I wonder if someone explains the difference in solexa sequencing and mRNA sequencing. thanks
I wonder if someone explains the difference in solexa sequencing and mRNA sequencing. thanks
-
-
"Solexa" is the name of a company purchased by Illumina some years ago. Sometimes still used to refer to sequencers now sold by Illumina, the term is losing currency as it does not seemed to be used by Illumina. Illumina sequencers are the most popular "next generation" sequencers, having come to dominate the nascent next gen market prior to their acquisition by Illumina.
"mRNA sequencing" would be a generic term for producing the sequence of at least part of a messenger RNA. There are many methodologies that allow mRNA (and, more commonly pools of mRNAs) to be sequenced on Illumina and many other sorts of sequencers.
--
Phillip -
thanks very much sir, It means both technologies are same but the name are different. mRNA sequencing could be named solexa sequencing?
thanks and regardsComment
-
No, not at all.
Many types of sequencing can be undertaken on an Illumina (Solexa) sequencer. This includes "mRNA sequencing", but is not limited to it.
Further, "mRNA sequencing" can be undertaken on many instruments.
So it is not correct to refer to "mRNA sequencing" as "solexa sequencing" or vice versa.
Repeating in Google-translated French:
Répétition dans Google-traduits française:
Non, pas tout.
De nombreux types de séquençage peuvent être entrepris sur une Illumina (Solexa) séquenceur. Ceci inclut "séquençage ARNm", mais n'est pas limité à qu'elle.
En outre, «séquençage ARNm» peut être entrepris sur de nombreux instruments.
Donc c'est pas correct pour désigner «ARNm séquençage» comme «Solexa séquençage» ou vice versa.
--
PhillipComment
-
Ok i got it, thanks againComment
-
Thank you, pmiguel, for your very nice answer and patienceComment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...Today, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM
Comment